{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:19:53Z","timestamp":1740136793480,"version":"3.37.3"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1124\/dmd.123.001629","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T23:58:37Z","timestamp":1709251117000},"page":"390-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Vitro to In Vivo Scalars for Drug Clearance in Nonalcoholic Fatty Liver and Steatohepatitis"],"prefix":"10.1016","volume":"52","author":[{"given":"Teresa","family":"Sierra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2595-5626","authenticated-orcid":false,"given":"Brahim","family":"Achour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001629_bib1","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1124\/dmd.111.040618","article-title":"Cytochrome P450 Pig liver pie: determination of individual cytochrome P450 isoform contents in microsomes from two pig livers using liquid chromatography in conjunction with mass spectrometry [corrected]","volume":"39","author":"Achour","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001629_bib2","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1124\/dmd.114.058834","article-title":"Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis","volume":"42","author":"Achour","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001629_bib3","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40262-022-01169-4","article-title":"Altered bioavailability and pharmacokinetics in Crohn\u2019s disease: capturing systems parameters for PBPK to assist with predicting the fate of orally administered drugs","volume":"61","author":"Alrubia","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001629_bib4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s11695-007-9041-2","article-title":"Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass","volume":"17","author":"Arun","year":"2007","journal-title":"Obes Surg"},{"key":"10.1124\/dmd.123.001629_bib5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/138920007779315053","article-title":"Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver","volume":"8","author":"Barter","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.123.001629_bib6","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1124\/dmd.108.021311","article-title":"Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling","volume":"36","author":"Barter","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001629_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/hepr.12338","article-title":"Impact of non-alcoholic fatty liver disease on liver volume in humans","volume":"45","author":"Bian","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1124\/dmd.123.001629_bib8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.123.001629_bib9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1124\/dmd.119.089656","article-title":"Quantitative proteomics of clinically relevant drug-metabolizing enzymes and drug transporters and their intercorrelations in the human small intestine","volume":"48","author":"Couto","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001629_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-pharmtox-033020-113257","article-title":"Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy","volume":"61","author":"Darwich","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.123.001629_bib11","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.1c00462","article-title":"Non-uniformity of changes in drug-metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment","volume":"18","author":"El-Khateeb","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.123.001629_bib12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/apt.16489","article-title":"Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment","volume":"54","author":"El-Khateeb","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1124\/dmd.123.001629_bib13","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1124\/dmd.120.000152","article-title":"Scaling factors for clearance in adult liver cirrhosis","volume":"48","author":"El-Khateeb","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001629_bib14","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1124\/dmd.109.027466","article-title":"Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease","volume":"37","author":"Fisher","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001629_bib15","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nprot.2009.121","article-title":"Measurement of cytochrome P450 and NADPH-cytochrome P450 reductase","volume":"4","author":"Guengerich","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1124\/dmd.123.001629_bib16","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.3748\/wjg.v27.i17.1864","article-title":"Non-alcoholic fatty liver and chronic kidney disease: retrospect, introspect, and prospect","volume":"27","author":"Heda","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1124\/dmd.123.001629_bib17","first-page":"55","article-title":"Combined hepatic vein, umbilicoportal vein, and superior mesenteric artery catheterization in portal hypertension: estimation of the portal fraction of total hepatic blood flow in cirrhotic patients","volume":"48","author":"Huet","year":"1975","journal-title":"Yale J Biol Med"},{"key":"10.1124\/dmd.123.001629_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1155\/1996\/15760","article-title":"A new method to measure portal venous and hepatic arterial blood flow in patients intraoperatively","volume":"9","author":"Jakab","year":"1996","journal-title":"HPB Surg"},{"key":"10.1124\/dmd.123.001629_bib19","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1021\/acs.molpharmaceut.8b00159","article-title":"Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver","volume":"15","author":"Jamwal","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.123.001629_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11318160-000000000-00000","article-title":"A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance","volume":"49","author":"Johnson","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001629_bib21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/lt.20519","article-title":"Changes in liver volume from birth to adulthood: a meta-analysis","volume":"11","author":"Johnson","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1124\/dmd.123.001629_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/dmd.121.000623","article-title":"Ontogeny of scaling factors for pediatric physiology-based pharmacokinetic modeling and simulation: microsomal protein per gram of liver","volume":"50","author":"Leeder","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001629_bib23","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3748\/wjg.v9.i9.2092","article-title":"Evaluation of liver functional reserve by combining D-sorbitol clearance rate and CT measured liver volume","volume":"9","author":"Li","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1124\/dmd.123.001629_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1210\/endrev\/bnz009","article-title":"Nonalcoholic fatty liver disease in adults: current concepts in etiology, outcomes, and management","volume":"41","author":"Marjot","year":"2020","journal-title":"Endocr Rev"},{"key":"10.1124\/dmd.123.001629_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1440-1746.1996.tb01699.x","article-title":"Hepatocyte volume as an indicator of hepatic functional reserve in cirrhotic patients with liver tumours","volume":"11","author":"Matsui","year":"1996","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1124\/dmd.123.001629_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2165\/00003088-199121010-00004","article-title":"Clinical pharmacokinetics in patients with liver disease","volume":"21","author":"McLean","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001629_bib27","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3109\/03602532.2011.577781","article-title":"Drug metabolism alterations in nonalcoholic fatty liver disease","volume":"43","author":"Merrell","year":"2011","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.123.001629_bib28","first-page":"733","article-title":"Receptor measurements via Tc-GSA kinetic modeling are proportional to functional hepatocellular mass","volume":"42","author":"Miki","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1124\/dmd.123.001629_bib29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cpt.2614","article-title":"Considerations for physiologically based modeling in liver disease: from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH)","volume":"113","author":"Murphy","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001629_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ddtec.2021.06.002","article-title":"Application of proteomic data in the translation of in vitro observations to associated clinical outcomes","volume":"39","author":"Neuhoff","year":"2021","journal-title":"Drug Discov Today Technol"},{"key":"10.1124\/dmd.123.001629_bib31","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00464-020-07490-y","article-title":"Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients","volume":"35","author":"Ooi","year":"2021","journal-title":"Surg Endosc"},{"key":"10.1124\/dmd.123.001629_bib32","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20150896","article-title":"Morphometric changes in liver cirrhosis: aetiological differences correlated with progression","volume":"89","author":"Ozaki","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1124\/dmd.123.001629_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/clpt.2012.65","article-title":"Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology","volume":"92","author":"Rostami-Hodjegan","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001629_bib34","series-title":"Advances in Pharmacokinetics and Pharmacodynamics","first-page":"137","article-title":"On the Verge of Impossibility: Accounting for Variability Arising from Permutations of Comorbidities that Affect the Fate of Drugs in the Human Body","author":"Rostami-Hodjegan","year":"2023"},{"key":"10.1124\/dmd.123.001629_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/dmd.121.000359","article-title":"Hepatic scaling factors for in vitro-in vivo extrapolation of metabolic drug clearance in patients with colorectal cancer with liver metastasis","volume":"49","author":"Vasilogianni","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001629_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2022.104601","article-title":"Proteomic quantification of perturbation to pharmacokinetic target proteins in liver disease","volume":"263","author":"Vasilogianni","year":"2022","journal-title":"J Proteomics"},{"key":"10.1124\/dmd.123.001629_bib37","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/cpt.2558","article-title":"Drug disposition protein quantification in matched human jejunum and liver from donors with obesity","volume":"111","author":"Wegler","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001629_bib38","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1124\/dmd.115.065979","article-title":"CYP3A activity and expression in nonalcoholic fatty liver disease","volume":"43","author":"Woolsey","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001629_bib39","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1124\/dmd.123.001629_bib40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejrad.2008.09.032","article-title":"Dynamic measurements of total hepatic blood flow with Phase Contrast MRI","volume":"73","author":"Yzet","year":"2010","journal-title":"Eur J Radiol"},{"key":"10.1124\/dmd.123.001629_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0168-8278(95)80326-2","article-title":"Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis","volume":"23","author":"Zoli","year":"1995","journal-title":"J Hepatol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624011607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624011607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:16:41Z","timestamp":1739956601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624011607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0090955624011607"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001629","relation":{},"ISSN":["0090-9556"],"issn-type":[{"type":"print","value":"0090-9556"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Vitro to In Vivo Scalars for Drug Clearance in Nonalcoholic Fatty Liver and Steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001629","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}